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Introduction
Migraine is a chronic neurological disorder characterized by recurrent headaches lasting for 4-72 
hours and commonly accompanied by nausea, photophobia and phonophobia. This syndrome 
affects 16% of the total population and its incidence is three times more common in women than 
in men. The total cost of healthcare for patients with migraine in Europe in 2010 was 18.4 billion 
€. 
It is well-known, that the activation and sensitization of the trigeminal system is essential during 
the attack. Continuous activation of peripheral trigeminal afferents leads to peripheral (first order) 
sensitization, which manifests as a throbbing pain worsening during physical activity (Burstein et 
al., 2011). Sustained nociceptive inputs can lead to sensitization of the second and ultimately to 
the third order neurons so called central sensitization manifested as allodynia when non painful 
stimuli are perceived as painful.
Despite the intensive research, the exact pathomechanisms of the migraine is not fully known, 
but the role of glutamate seems pivotal. One of the endogenous glutamate receptor antagonists is 
kynurenic acid (KYNA), which is produced by the kynurenine pathway. 
KYNA is believed to be a neuroprotective metabolite of tryptophan that interacts with glutamate 
receptors, aryl hydrocarbon receptor, G protein-coupled receptor 35 and elicits anti-glutamatergic 
actions. Several lines of data confirm that KYNA and its analogues have anti-nociceptive effects in 
several migraine-models, probably by attenuating the trigeminal activation and sensitization. The 
first step in the kynurenine pathway is the conversion of tryptophan to N-formyl-L-kynurenine by 
tryptophan 2,3‑dioxygenase (TDO2) and indoleamine 2,3‑dioxygenase (IDO1,2): the rate-limiting 
enzymes of tryptophan metabolism. N‑formyl-L-kynurenine is further degraded by formamidase 
to L-kynurenine (L-KYN), which is converted to KYNA by kynurenine aminotransferases (KAT)
s, to 3-hydroxykynurenine by L-kynurenine 3-monooxygenase (KMO) and to anthranilic acid by 
L-kynurenine hydrolase (KYNU).
Animal models of pain have shown that fluctuations in the endocannabinoid levels in the 
nervous system are related to pain processing and antinociception. N-Arachidonylethanolamide 
or anandamide (AEA) is the first discovered endocannabinoid, and is an agonist of cannabinoid 
receptors (CBs) and transient receptor potential vanilloid type 1 (TRPV1).
An increasing amount of evidence suggests that nitroglycerin (NTG) is able to activate and 
sensitize the trigeminal system in humans. One of the side-effects of NTG is headache due to 
vasodilatation induced by nitric oxide (NO), which occurs immediately after its administration, 
but about four hours later it is followed by a typical migraine without aura in migraine patients, 
which can not be attributed to NO’s prompt vasodilator effect. This observation and the results 
of a pilot study showing that treatment with nitric oxide sysnthase (NOS) inhibitor attenuates 
spontaneous migraine headaches in 67% of subjects, contributed to the implication of NO in 
migraine pathogenesis. 
It is well known that AEA is able to reduce NTG-induced hyperalgesia and c-Fos expression in 
the caudal trigeminal nucleus (TNC) in rats, which means that AEA is capable of modulating the 
activation of the trigeminal system.
TRPV1 is a nonselective cation channel activated by numerous stimuli, such as heat and vanilloids. 
It is present in the spinal cord and is considered as a molecular integrator of chemical and physical 
stimuli that elicit pain. In addition, NO donors can activate TRPV1 resulting in an increase of 
intracellular calcium concentration in different cell types, which suggests that TRPV1 may be 
modulated by NO.
NO is synthesized from arginine by NOS, neuronal isoform of which (nNOS) has an outmost 
importance in nociception and sensitization and it is present in the trigeminal system. NO donors 
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may trigger a self-amplifying process at the level of central projection site of the trigeminal 
system by increasing endogenous NO synthesis, which might be relevant in central sensitization 
phenomenon.
Nuclear factor kappa B (NF-κB) has a crucial role in inflammation process by controlling many 
genes including cytokynes. Several studies have shown that proinflammatory cytokynes contribute 
to the development of pain and hyperalgesia. Cyclooxygenase-2 (COX-2) is present in the dorsal 
horn of spinal cord too and it has a substantial role in the processing of pain. COX formally 
known as prostaglandin-endoperoxide synthase, is an enzyme that is responsible for formation of 
prostanoids, including thromboxane and prostaglandins such as prostacyclin.
Gao and Duan have found that COX-2 expression increased in the TNC after orofacial nociception.
Aims
1. The purpose of our studies was to investigate the modulatory effects of a CB agonist AEA 
on the NTG-induced expression of the markers of the sensitization process, namely TRPV1, 
nNOS, NF-κB and COX-2. 
2. Furthermore, our aim was to examine the effect of NTG on the expression of the enzymes 
of the kynurenine pathway, as TDO2, IDO1, KAT-II, KYNU and KMO.
Materials and methods
Animals
We followed the directives for the Use of Animals in Research of the International Association 
for the Study of Pain and the policy of the European Economic Community (86/609/ECC). They 
were authorized by the local ethical committee of University of Szeged and the Scientific Ethics 
Committee for Animal Research of the Protection of Animals Advisory Board (XXIV./352/2012). 
54 adult male Sprague-Dawley rats of 200-250 g bodyweight were used. The rodents were raised 
and maintained under standard laboratory conditions with tap water and regular rat chow available 
ad libitum on a 12 hour dark-12 hour light cycle.
Drug administration
Examination of the sensitization markers: 
The animals were divided into four groups (n=6 per group for immunohistochemistry, n=5 per 
group for Western blot analysis). 
The animals in the first group, called placebo group, received only the vehicle solution (physiological 
saline) as treatment. In the second group, the rats were treated with an intraperitoneal injection of 
NTG (10 mg/kg bodyweight, Pohl Boskamp). In the third and fourth group, animals received 
intraperitoneal AEA (2x5 mg/kg bodyweight, Sigma Aldrich) half hour before and one hour after 
the placebo or NTG treatment. AEA was dissolved in physiological saline. In the case of the first 
and second groups, animals were treated with physiological saline instead of AEA. 
Kynurenine pathway experiment:
The animals were separated into two groups (n = 5). The animals in the first group, called placebo 
group, received only the vehicle solution (physiological saline) as treatment. In the second group, 
the rats were treated with an intraperitoneal injection of NTG (10 mg/kg bodyweight, Pohl 
Boskamp).
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Immunohistochemistry
Four hours after the placebo/NTG injection, the rats were perfused transcardially and the upper 
cervical spinal cord (C1-C2) segments of the cervical spinal cord between (-5) and       (-11) mm from 
the obex were removed and postfixed overnight for immunohistochemistry. After cryoprotection, 
30 μm thick serial sections were cut from the C1-C2 and were processed for TRPV1, nNOS and 
NF-κB immunohistochemistry. The area covered by TRPV1-immunoreactive fibres and nNOS-
immunoreactive cells was determined by Image Pro Plus 6.2® image analysis software (Media 
Cybernetics). After image acquisition, the laminae I-II in dorsal horn were defined manually as 
area of interest and a threshold grey level was validated with the image analysis software, as 
described in an earlier study. The program calculated the area innervated by the immunoreactive 
fibres and cells as the number of pixels with densities above the threshold, the data were expressed 
as area fractions (%) of the corresponding immunolabelled structures.
We used the unbiased optical disector method to calculate the volume densities of the NF-κB-
immunoreactive cells.
Western blot analysis
Four hours after the placebo/NTG injection, the rats (n=5 per subgroup) were deeply anaesthetized 
with chloral hydrate, perfused transcardially and the C1-C2 segments of the cervical spinal cord 
between (-5) and (-11) mm from the obex and TNC between 1 and (-5) mm from the obex were 
removed and processed for nNOS, COX-2, β-actin, TDO2, IDO1, KAT-II,  KYNU,  KMO or 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) Western blotting.
Results
Immunohistochemistry
On transverse sections of the C1-C2 segments, there were abundant TRPV1-positive fibres, nNOS-
immunoreactive neurons, NF-κB-positive cells in the superficial layers of the dorsal horn. The 
area covered by IR fibres and the number of IR cells did not differ significantly between sections 
located at the various levels along the rostrocaudal axis or between the right and left dorsal horns 
of the cervical segments. 
The TRPV1-immunoreactive area in the NTG-treated group was significantly higher compared to 
the placebo-treated group (p<0.05). Furthermore, in the NTG group, the area fraction of nNOS-
immunoreactive structures and the volume density of NF-κB-positive cells were significantly 
higher than in the placebo-treated group (p<0.01), (p<0.05).
AEA treatment resulted in a decrease of TRPV1-immunoreactice area (p<0.05) and 
nNOS-immunopositive structures (p<0.001), as well. NF-κB-positive cells were also decreased in 
the AEA injected group (p<0.05).
Western blotting
Western blotting analysis of the C1-C2 region confirmed the results obtained by nNOS 
immunohistochemistry. Densitometric analyses confirmed that the nNOS bands (155 kDa) were 
significantly enhanced (p<0.01) in dorsal horn of C1-C2 segments after NTG administration 
as compared with the placebo-treated animals. This effect of NTG on nNOS was attenuated by 
treatment with AEA (p<0.05). 
A band characteristic of the COX-2 protein was identified at 68 kDa in Western blot assay. Statistical 
analyses showed that the COX-2 bands were significantly enhanced (p<0.01) in segments C1-C2 
after NTG administration as compared with the placebo-treated animals. The effect of NTG was 
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decreased by the AEA treatment (p<0.01). 
The TDO2 protein was identified at 50 kDa in Western blot assay. The TDO2 bands were 
significantly decreased (p < 0.05) in the TNC after NTG administration as compared with the 
placebo-treated animals.
IDO1 protein was referred at 45 kDa in Western blot assay. Densitometric analyses confirmed 
that the IDO1 bands were significantly weaker (p < 0.05) in the TNC after NTG administration 
as compared with the placebo-treated animals. 
A band characteristic of the KAT-II protein was referred at 60 kDa in Western blot assay. Statistical 
analyses confirmed that the KAT-II bands were significantly weaker (p<0.05) in segments C1-C2 
after NTG administration as compared with the placebo-treated animals. 
We could identify a band at 35 kDa characteristic for the KYNU protein. In animals, which had 
received NTG, the density of KYNU protein bands was weaker in TNC segments (p < 0.05) as 
compared with the placebo-treated group.
KMO protein was identified at 56 kDa in Western blot assay. Densitometric analyses showed that 
the KMO bands were significantly decreased (p < 0.05) in segments TNC after NTG administration 
as compared with the placebo-treated animals.
Discussion
TRPV1 is present in the terminals of primary sensory neurons in the dorsal part of spinal cord 
and co-expressed with CB1. Experimental data indicate that TRPV1 contributes to peripheral 
sensitization, allodynia and hyperalgesia, central blockade of this receptor is able to attenuate 
central terminal sensitization. Our results show that NTG significantly increases TRPV1 expression 
in the C1-C2 segments of the rat, thus it may be the indicator of sensitization phenomena in the 
trigeminal system in our experimental setting.
It is well established that NO donors can activate TRPV1 in several cell types and in inflammatory 
pain models increased receptor expression was also reported. This indicates that the NTG effect 
on TRPV1 expression is indirect - it may cause neurogenic inflammation, and the inflammatory 
mediators - like serotonin (5-HT), bradykinin (BK), etc. - can activate TRPV1 by stimulating 
trigeminal nociceptive neurons. Pro-inflammatory mediators, such as tumor necrosis factor 
α, interleukin 1 (IL-1), interleukin 6 (IL-6) and BK enhance TRPV1. In the animal model of 
inflammation, Complete Freud’s adjuvant increases TRPV1 mRNA expression in the dorsal 
root ganglion, this also supports the idea that inflammation upregulates TRPV1 expression. 
To summarize, we may assume that NTG is able to activate TRPV1 mainly via inflammatory 
mediators. On the other hand, there are research data indicating that systemic administration of 
calcitonin gene-related peptide (CGRP) increases the expression of TRPV1 in the TG of rats, 
which might also play a role in this process. NTG can increase the release of CGRP by NO-
mediated stimulation of Aδ and C fibers.
Our recent data also show that AEA, a CB receptor and TRPV1 agonist attenuates the effect of 
NTG on TRPV1 changes. Activation of ionotropic CBs can result in inhibition of nociceptors 
and antihyperalgesia and antinociception in certain pain models. Intrathecal administration of 
AEA decreases thermal pain sensitivity and its effect can be altered with the TRPV1 antagonist 
capsazepine. AEA may also cause a desensitization of TRPV1 in skeletal muscle arterioles, 
suggesting that AEA is able to mitigate TRPV1 activity. On the other hand, AEA can inhibit 
neurogenic, CGRP- and NO-induced dural vasodilatation, and this involves pre- and postsynaptic 
mechanisms. Recent report shows that the AEA level changes are able to modulate CGRP mRNA-
expression after NTG-treatment in human peripheral blood mononuclear cells. We do not know 
exactly the role of TRPV1 in the AEA modulated sensitization process, but based on the available 
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literature data, we hypothesize that the role of CB1 is more pronounced than TRPV1 in this context. 
It is known that nNOS is a key player in nociception and its role in the sensitization cascade is 
intensively studied. In our present experiment administration of NTG increased the expression of 
nNOS in the C1-C2, which is in line with earlier results. The most probable explanation for this 
phenomenon is, that NO activates small caliber fibres in the trigeminal system and the increase of 
nNOS expression in the second order trigeminal neurons induces a self-amplifying mechanism. 
The present results indicate that AEA is able to inhibit this effect. Several studies have shown that 
there is an interaction between NO and cannabinoid system e.g. nNOS and CB1 are co-localized in 
neurons in lamina II of the spinal cord. NTG-induced hyperalgesia is associated with a fluctuation 
of the activity of endocannabinoid system in various brain areas of rats. Our data are in line with 
Hillard and co-workers findings, who reported that CB1 agonists inhibit KCl-induced activation 
of nNOS in cultured cerebellar granule cells. In addition, Carney and co-workers have detected 
that cannabinoid agonist downregulated nNOS protein and mRNA in neuronal cells. These data 
suggest that NTG is able to generate sensitization process and AEA inhibits this effect by blocking 
nNOS.
In our experiment NTG increased NF-κB expression in the superficial layers of the dorsal horn 
in the C1-C2 segments. Similar effect was reported by Reuter et al., who demonstrated that NTG 
infusion is able to trigger the activation of NF-κB in dura mater. It is not clear how NTG can 
activate NF-κB-pathway, it might be related to a direct neuronal effect of NTG, or indirect effect 
via dural inflammation. Concerning the cellular mechanisms it is important to note that both 
TRPV1 and nNOS might play a role in this effect. It was shown that Ca2+ influx through TRPV1 
may modulate the nuclear translocation and increased the activity of NF-κB. On the other hand 
the increase in nNOS expression is accompanied by increased NF-κB expression and activation. 
Furthermore, Sancho and colleagues have noticed that AEA inhibits tumor necrosis factor-α-
induced activation, by inhibition of a cytokine-induced cascade. In addition, Nakajima and co-
workers have found that AEA also blocked lipopolysaccharide-induced activation, suggesting that 
AEA inhibits proinflammatory mediators by blocking NF-κB activation. Tassorelli and her group 
reported that parthenolide (inhibitor of NF-κB) attenuated NTG-induced c-Fos activation in TNC, 
which indicates that NF-κB may be important in the NTG-induced trigeminal activation and its 
inhibition is able to modulate the nociceptive process. Our data reconfirm, that NTG is able to 
activate NF-κB, thus can trigger neurogenic inflammation, which has a key role in sensitization 
phenomena. Furthermore, we detected that AEA is able to reduce this effect. Endocannabinoids 
might operate a negative feedback control over the proinflammatory process by suppressing the 
activation of transcription factors involved in the inflammatory action.
NO may also cause neurogenic inflammation by increasing NF-κB levels, which may lead to 
the upregulation of COX-2 in inflammatory pain. It is well-known, that NSAIDs, which exert 
their effects through the inhibition of COX-enzymes, are effective in the treatment of migraine 
and tension-type headache. In animal studies, it has been shown that COX-2 is involved in the 
NTG-induced activation and sensitization process of the trigeminal system. Pre-treatment with 
indomethacin (non-selective COX inhibitor) and NS398 (selective COX-2 inhibitor) reduced the 
NTG-induced c-Fos, nNOS and calmodulin-dependent protein kinase II alpha expression-changes 
in the TNC. Tassorelli and colleagues have demonstrated that COX-2 expression is increased in 
the hypothalamus and caudal brain stem after NTG injection, thus COX is one of the mediators 
of NTG-induced neuronal activation. Furthermore, NO is able to activate COX-enzymes in 
fibroblasts, probably by an interaction with the iron-hem center of the enzyme (Salvemini et al., 
1993). It is important to note, that AEA is one of the substrates of COX-2 producing prostaglandin 
and ethanolamids. In our study, we have found that AEA is able to inhibit the NTG-induced COX-
2 increase. Our assumption is that it may be associated with a negative feedback mechanism, but it 
is possible that after the cleavage of AEA some metabolites may downregulate COX-2 expression. 
Since AEA is able to reduce cytokine-induced cascade and proinflammatory mediators (Nakajima, 
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2006), it is also possible, that the reduction of the inflammatory process is able to downregulate 
the COX-2 expression.
In our experiments NTG decreased the expression of the kynurenine pathway in the TNC and C1-C2 
segments, which may indicate that fluctuation of these enzymes is involved in the NTG-triggered 
trigeminal activation. However, the question arises how NTG /NO can influence the kynurenine 
pathway. It is well-known that the nitrergic-system is able to alter the kynurenine system, e.g. NO 
inhibits IDO expression by reversible binding to the active site in macrophages and IDO activity 
is down-regulated by NO production in bone marrow cells. The other hand, it is also known that 
the expression of KMO influences NO production in human HEK293 cells. Moreover, Backhaus 
and her colleagues showed in a mass spectrometry and NMR study that there is a direct interaction 
between kynurenine metabolites, e.g., 3-hydroxykynurenine and 3-hydroxyanthranilic acid and 
NO.
It is also important to note that kynurenines have a crucial role in immune regulation. The 
transcriptional expression of IDO, KAT-II, KMO, KYNU is also under the control of interferons, 
thus pro-inflammatory cytokines influence kynurenine pathway. Lögters and co-workers have 
shown that the kynurenine-tryptophan ratio was increased in the blood of patients with posttraumatic 
sepsis, proving that inflammation could modulate the kynurenine pathway. 
In this context, it is pivotal that NO may cause neurogenic inflammation in the central nervous 
system. This is supported by observations, that NTG was able to increase the expression of NF-
κB in the trigeminocervical complex of rats, which is a key player in the inflammation process 
controlled by cytokines. In human studies, Tfelt-Hansen and his group demonstrated that infusion 
of NTG can trigger inflammatory response by inducing inflammatory mediators, which response 
was inhibited by the anti-inflammatory drug, prednisolone. 
On the other hand migraine can be characterized by an increase in glutamatergic function (Vecsei 
et al., 2013), yielding fully activated NMDA receptors by the high glutamate levels, which 
might be associated with low KYNA levels. Increased glutamate levels were found in the human 
cerebrospinal fluid, plasma and platelets of migraineurs.
Our findings are comparable with recent studies, which showed that chronic migraine and cluster 
headache are associated with altered levels of kynurenine metabolites, i.e., reduced levels of 
KYNA and L-KYN has been found in the serum of these patients. These findings are in accordance 
with the context of an increased release of glutamate might yielding to a hyperactivity of glutamate 
receptors. 
To summarize the human and animal data, we can conclude that the kynurenine pathway is down-
regulated under the different types of headaches and thus possibly providing less KYNA. These 
data are in line with the theory of hyperactive NMDA receptors having a role in the migraine 
pathophysiology since these receptors are key players in the mechanism of central sensitization, 
which is important in migraine pathophysiology. 
Conclusion
The present data indicate that (i) NTG treatment activates the trigeminal system and the observed 
changes can be interpreted as a central sensitization phenomenon. Furthermore, (ii) NTG induced 
alterations are reversed by the administration of AEA suggesting the involvement of CBs in this 
process. Item, (iii) NTG is able to down-regulate the kynurenine pathway, with a potential influence 
on the glutamatergic system as well, contributing to the development of trigeminal activation and 
sensitization in animals.
These data suggest that the endocannabinoid system plays a significant role in the cellular mechanism 
of trigeminal sensitization and thus it may modulate the pathomechanism of migraine. Our present 
data strongly confirm that the kynurenine system has a relevant role in the pathomechanism of 
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the trigeminal activation and sensitization, thus in the migraine pathology, as well. In summary, 
influencing the kynurenine pathway provides a possible new target in the future therapy of migraine.
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